Novel Preparative Regimens in Hematopoietic Stem Cell Transplantation

Lekakis, Lazaros J.; Silva, Leandro de Pádua; Lima, Marcos de

doi:10.2174/138161208785061409

Cited by 10 publications

(4 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conditioning regimens, chronic immune suppression, and graft-versus-host disease present significant challenges for cellular transplantation (1, 2). To avoid the need to modulate the immune system, cell encapsulation devices have been considered (3, 4).…”

Section: Introductionmentioning

confidence: 99%

Real-Time Bioluminescence Imaging of Macroencapsulated Fibroblasts Reveals Allograft Protection in Rhesus Monkeys (Macaca mulatta)

Tarantal

Lee²,

Itkin-Ansari

2009

Transplantation

View full text Add to dashboard Cite

Background Encapsulation of cells has the potential to eliminate the need for immunosuppression for cellular transplantation. Recently, the TheraCyte® device was shown to provide long-term immunoprotection of murine islets in the NOD/SCID mouse model of diabetes. In this report, translational studies were undertaken using skin fibroblasts from an unrelated rhesus monkey donor that were transduced with an HIV-1-derived lentiviral vector expressing firefly luciferase permitting the use of bioluminescence imaging (BLI) to monitor cell survival over time and in a noninvasive manner. Methods Encapsulated cells were transplanted subcutaneously (N=2) or cells were injected without encapsulation (N=1) and outcomes compared. BLI was performed to monitor cell survival. Results The BLI signal from the encapsulated cells remained robust post-insertion, and in one animal persisted for up to 1 year. In contrast, the control animal that received unencapsulated cells exhibited a complete loss of cell signal within 14 days. Conclusions These data demonstrate that TheraCyte® encapsulation of allogeneic cells provides robust immune protection in transplanted rhesus monkeys.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-Time Bioluminescence Imaging of Macroencapsulated Fibroblasts Reveals Allograft Protection in Rhesus Monkeys (Macaca mulatta)

Tarantal

Lee²,

Itkin-Ansari

2009

Transplantation

View full text Add to dashboard Cite

show abstract

“…Such myeloablative conditioning regimens can potentially lead to a high incidence of transplant related complications that may result in patient mortalities. However, in the last two decades, there has been a significant reduction in transplant related mortality (TRM), largely because of the use of less toxic, yet effective, preparative regimens as well as improvements in supportive care [16]. Traditional conditioning regimens have been enhanced by the incorporation of newer drugs that target specific hematopoietic cells (like rituximab) as well as other drugs with less toxicity and higher anti-tumor effects like treosulfan [17], thiotepa [18] and radiolabelled antibodies [19].…”

Section: Improving Hsct Outcomes Novel Preparative Regimens and Suppomentioning

confidence: 99%

Improving The Efficacy And Availability Of Stem Cell Transplant Therapies For Hematopoietic Stem Cell Transplantation

Hwang

Poon²,

Bari³

2014

J Stem Cell Res Ther

View full text Add to dashboard Cite

Recent developments in pre-transplant preparative regimens as well as post-transplant care have made incremental but definite improvements in post-transplant survival. Graft engineering has also helped to facilitate the removal of cells which cause graft-versus-host disease (GVHD), the eradication of cells which might cause relapse, the expansion of donor cells when there is an inadequate cell dose, and the addition of selected cells to improve graft function with augmented anti-tumor or anti-infective properties. These advances help enhance the safety, efficacy and availability of HSCT, ensuring that this modality of treatment remains an important part of the continuum of care of patients of potentially fatal cancers and blood diseases.

show abstract

“…blood precursor cells (PBPC) and a better support therapy [26]. In the CORAL trial, there were three deaths reported (TRM 1.4%) due to toxicity among 206 chemosensitive relapsed patients with DLBCL after BEAM [27].…”

Section: Review Musso Porretto Scalone Crescimanno Polizzi and Bonannomentioning

confidence: 99%

Novel Conditioning Regimens for Hodgkin‘S and Non-Hodgkin‘S Lymphoma

Musso

Porretto

Scalone

et al. 2014

Int. J. Hematol. Oncol.

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT), in chemosensitive relapsed patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), is associated with superior event-free survival (EFS) compared with salvage chemotherapy alone. BEAM is one of the most commonly used regimens in both HL and NHL because of its acceptable toxicity and high effectiveness. The nonrelapsed mortality (NRM) ranges from 7 to 10% in historical studies. More recent investigations have demonstrated a lower NRM, probably due to various factors such as the use of peripheral blood precursor cells and better support therapy. Recently, in order to reduce the toxicity of carmustine and increase antilymphoma activity, several groups have introduced conditioning regimens similar to BEAM. The incorporation of newer drugs (anti-CD20 monoclonal antibodies ± radiolabeled) to 'classic' BEAM, or the substitution of carmustine with other drugs (thiotepa, bendamustine and High-dose chemotherapy (HCT) followed by autologous stem cell transplantation (ASCT) represents a valuable strategy for chemosensitive relapsed patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), and shows superior event-free survival compared with salvage chemotherapy alone.BEAM, which includes carmustine (BCNU), etoposide, cytarabine and melphalan, is one of the most commonly used regimens in both HL and NHL because of its acceptable toxicity and high effectiveness.The nonrelapsed mortality (NRM) of BEAM has been shown to range from 7 to 10% in historical studies. More recent investigations have demonstrated a lower NRM, probably due to various factors such as the use of peripheral blood precursor cells and better support therapy.Recently, in order to reduce the toxicity of BCNU and increase its antilymphoma activity, several study groups have introduced conditioning regimens similar to BEAM.Radioimmunotherapy-based conditionings have a relapse incidence similar to total body irradiation, but with lower toxicity, resulting in improved overall survival.The second-generation BEAM regimens, in which BCNU is substituted with other drugs (i.e., thiotepa, bendamustine and fotemustine), may be a valuable strategy to further reduce toxicity and increase the antilymphoma activity of ASCT.

show abstract

Novel Preparative Regimens in Hematopoietic Stem Cell Transplantation

Cited by 10 publications

References 90 publications

Real-Time Bioluminescence Imaging of Macroencapsulated Fibroblasts Reveals Allograft Protection in Rhesus Monkeys (Macaca mulatta)

Real-Time Bioluminescence Imaging of Macroencapsulated Fibroblasts Reveals Allograft Protection in Rhesus Monkeys (Macaca mulatta)

Improving The Efficacy And Availability Of Stem Cell Transplant Therapies For Hematopoietic Stem Cell Transplantation

Novel Conditioning Regimens for Hodgkin‘S and Non-Hodgkin‘S Lymphoma

Contact Info

Product

Resources

About